The American Society of Hematology’s (ASH) 61st Annual Meeting & Exposition is the premier annual conference for malignant and non-malignant hematology. They work hard to bring new levels of collaboration and advocacy to find better treatments. Thank you to ASH for providing a wonderful interactive forum for advanced learning.

I’ve been going to ASH for a long time, and it has evolved to be the forum to learn and share clinical information. This year, 30,000+ hematology professionals (40% of them from outside the U.S.) from every subspecialty came to learn the latest in cutting-edge science. They also came to find what they can use in their everyday clinical practices.

The biggest takeaway? Hematology is moving towards novel curative treatments that improve the course, and decrease the burden, of life-long treatment interventions.

For diseases such as sickle-cell disease and difficult-to-treat aggressive lymphoma, leukemia, and myeloma, patients will benefit from novel therapeutics such as new stem-cell based therapies (bi-specific antibodies and CAR-T) and newer generation BTK inhibitors. The opportunity to change the landscape for these disorders can lead to cures or improvement in patients’ quality of life by decreasing the number of interventions performed.

The biggest takeaway?
Hematology is moving towards novel curative treatments that improve the course, and decrease the burden, of life-long treatment interventions. These targeted therapies require targeted, adaptive clinical trials.

Targeted Therapies Require Targeted, Adaptive Clinical Trials

For all of these therapeutic advances to reach patients, it will require clinical research and data in highly specific patient populations. Clinical research of highly specific and smaller populations requires new levels of precision in devising and conducting successful clinical trials. This makes the process of identifying and enrolling patients even more critical.

We see great potential coming out of ASH this year. Inteliquet can help by improving the process of identifying  patients that meet rigorous inclusion criteria via our data, our technology and our clinical expertise. Inteliquet  looks forward to moving the needle on bringing novel processes and technology to improve the clinical research process.

See you in 2020!

MENU
CONTACT US
© Copyright 2020 Inteliquet, Inc. All rights reserved.
© Copyright 2020 Inteliquet, Inc. All rights reserved.